SciELO - Scientific Electronic Library Online

 
vol.93 issue3Percutaneous aortic valve replacement for the treatment of aortic stenosis: early experience in BrazilOcclusion of the left coronary trunk secondary to tertiary syphilis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

Share


Arquivos Brasileiros de Cardiologia

Print version ISSN 0066-782X
On-line version ISSN 1678-4170

Arq. Bras. Cardiol. vol.93 no.3 São Paulo Sept. 2009

http://dx.doi.org/10.1590/S0066-782X2009000900016 

ORIGINAL ARTICLE

 

Joint hypermobility in patients with mitral valve prolapse

 

 

Simone Cavenaghi; Lais Helena Carvalho Marino; Patrícia Pantaleão Oliveira; Neuseli Marino Lamari

Faculdade de Medicina de São José do Rio Preto, SP, Brasil

Mailing address

 

 


SUMMARY

Studies on hypermobility have aroused great interest in the last decades, as they are associated to musculoskeletal disorders, as well as abnormalities in several organic systems, such as the mitral valve prolapse. Therefore, in this study, data on the association between joint hypermobility and the mitral valve prolapse were investigated and reviewed. Studies in the literature have shown that genetic alterations in the collagen composition seem to be the main cause of this association.

Key words: Mitral Valve Prolapse; Joint Instability; Physical Therapy; Collagen / Genetics.


 

 

Introduction

Association between joint hypermobility and mitral valve prolapse

Joint hypermobility (JH) was first mentioned by Hippocrates as an isolated feature, when he described the Celts' incapacity to pull a bowstring or throw a dart, due to the slackness of their limbs1. Known as the "enigma of human physiology", it arouse great interest in the last decades for being associated to musculoskeletal dysfunctions, as well as abnormalities in several organic systems and among them, the mitral valve prolapse (MVP)2.

The MVP is a common cardiovascular disorder, with a strong hereditary component, generally diagnosed in young individuals3 and characterized by the projection of mitral leaflets in the left atrium, often accompanied by mitral regurgitation4, organic deficiency of the papillary muscles and stretching or tearing of chordae tendineae5.

It can present as symptomatic cardiac arrhythmias and present as the asymptomatic form, thus, sudden death can occur in these patients. Therefore, the detection of the characteristics that can identify individuals with a higher probability of presenting MVP can be clinically opportune. It must also be considered that the alteration in collagen that characterizes JH and MVP makes it likely that individuals with MVP also would be more commonly hypermobile6.

This aim of the present study was to update the knowledge on the association between joint hypermobility and mitral valve prolapse in the general population, contributing to the diagnosis and prevention of the cardiovascular alterations.

Mitral valve prolapse

The MVP is a common clinical entity, with a prevalence of 2% to 22%7; according to the Framingham study, 7.6% of the women and 2.5% of the men in the USA have MVP8. The differences in the results of the epidemiological studies are a reflex of the different diagnostic criteria employed and the diversity of the study popualtions7.

Other data related to the prevalence of MVP suggest that it is uncommon before the adolescence, but its prevalence increases after the pubertal growth spurt9. Symptom onset does not take place before the adolescence (approximately 14 years in girls and 15 years in boys) and the adults can be affected at any age. Common symptoms include thoracic pain, fatigue, arrhythmia and low tolerance to exercise; however, most individuals are asymptomatic10.

Araujo and Chaves6 verified the presence of arrhythmias at rest and/or after exercise, behavior of the cardiac parasympathetic component, manual prehension strength or the physical performance itself, evaluated through oxygen consumption at the anaerobic threshold and maximum effort, of which results were similar in women with and without MVP.

In the last decade, new echocardiographic criteria were established, based on the understanding of the 3-D structure of the mitral valve, which defined the prolapse as the dislocation of one or both mitral leaflets for more than 2 mm over the high points of the mitral annulus. The prolapse is subdivided in classic and non-classic, which are based on the thickness of the leaflets: classic > 5 mm and non-classic < 5 mm. Complications such as endocarditis and severe mitral regurgitation can occur in patients with classic prolapse9. Longitudinal studies identified the increase in the leaflet thickness as the main factor of an unsatisfactory prognosis, with high risk of sudden death, bacterial endocarditis, arrhythmias and mitral regurgitation in those individuals with classic prolapse4,11.

The MVP is considered a multifactorial valvular abnormality, as it is caused by histological abnormalities of the valvular tissue, geometric disparities between the left ventricle (LV) and the mitral valve, or several disorders of the conjunctive tissue. The increased thickness and redundancy of the leaflet, known as myxomatous degeneration, are the most common abnormalities in addition to structural alterations of the collagen in all components of the leaflets and the abnormal structure of the chordae tendineae11.

It is known that there is an increase in the glycosaminoglycan content, alterations in types I and III collagen and disarray in the organization of the collagen and elastic fibers12. Moreover, recently, genetic abnormalities in specific loci of chromosomes 11, 13 and 16 have been related to the etiology of the prolapses3,4,13.

Although the autosomal dominant inheritance has been described for the MVP in conjunctive tissue disorders, as in Marfan syndrome, previous studies have failed in the attempt to establish an association between MVP and collagen genes. These negative results might have been due to the lack of a systematic analysis of the human genome and uncertainty of the phenotypic diagnosis.

A recent research included 43 individuals that lived with three-generation members, with a significant number of individuals presenting MVP and no characteristics of Marfan syndrome. A clinical and echocardiographic assessment was performed, as well as genome analysis, using a program called SLINK. Araujo and Chaves6 demonstrated a new autosomal dominant locus in MVP present in the long arm of chromosome 13. These findings confirmed the heterogeneity of the MVP, previously found in chromosomes 11 and 16 and in chromosome X13.

Some studies have also reported a high prevalence of MVP in specific populations, similarly to Marfan and Ehlers-Danlos syndromes, somehow suggesting biological associations among them14,15.

In addition to the association with JH, individuals with MVP present an increased risk of developing infectious endocarditis, due to the turbulent flow caused by the mitral regurgitation and increased thickness of the valvular tissue, as well as increased risk of ischemic and cerebrovascular events, especially in young patients11, panic syndrome, anxiety, agoraphobia16 and hypothyroidism17.

Joint hypermobility

Joint Hypermobility (JH) is defined as the capacity to perform articular movements with a higher range of motion than the normal one18,19. Its prevalence depends on the characteristics of the studied group determined, among others, by age, sex, ethnicity and genetic factors that have an effect on the process of movement evolution. Studies have stated that female individuals have a higher joint mobility than male individuals and that it decreases with age20,21. Approximately 30% of the adult individuals are considered as presenting JH22.

The features of JH that appear in some hereditary diseases such as Marfan syndrome, Osteogenesis Imperfecta, Achard syndrome, Homocystinuria and Hyperlysinemia must be differentiated from those present in the general population1.

All cases present an association with collagen structure alterations, more specifically type III collagen and alterations in the genes involved in the production of fibrillin19,23 and, furthermore, with the laxness of ligaments, skin, blood vessels and adjacent muscular tissues1,2.

JH in the general population is a common condition and a genetically determined one22. There is a new consensus that the Benign Joint Hypermobility Syndrome (BJHS) is a multisystemic disorder, of which characteristics coincide with the characteristics of the hereditary disorders of the conjunctive tissue, which include Marfan syndrome, Ehlers-Danlos syndrome and Osteogenesis Imperfecta23. To date, the genetic basis of common hypermobility remains unknown; however, studies of hereditary disorders of the conjunctive tissue provided important discoveries on the underlying mechanisms of JH.

Mutations in the COL3A1 gene were found, codifying type III collagen. Recently, mutations in the non-collagen molecule tenascin-X, a large glycoprotein extracellular matrix, have been identified in a subset of diseases such as Ehlers-Danlos syndrome and Joint Hypermobility Syndrome. Mutations in the collagen type I gene (COL1A1 and COL1A2) also have an important role in the pathogenesis of JH19.

Focusing on diagnosis, Araujo24 sought to correlate different linear and adimensional methods of assessment of joint mobility. A total of 30 asymptomatic individuals participated, 16 males and 14 females. The sit-and-reach test, Toe-touch, Beighton-Horan, Rosembloom and Flexitest were used, with the latter being the only method that significantly correlated with the others (p<0.005) and incorporated relevant aspects of each one of them. A better association was observed between the Flex-Index and Beighton-Horan, as they presented a higher degree of similarity. They emphasized that tests developed several decades ago continue to be used routinely, despite their known limitations.

The Flexitest is a passive assessment method of 20 joint movements (Table 1), using a scale of whole numbers between 0 and 4 for each movement (Figures 1 and 2). The ankle, knee, hip, trunk, wrist, elbow and shoulder joints are assessed2, while the method by Beighton-Horan consists in the assessment of joint mobility in the little finger, wrist, elbow, knee and trunk. The angular values and bilateral analyses are obtained with a goniometer, except for the vertebral column and wrist variables20,21.

 

 

 

 

 

 

Mitral valve prolapse and joint hypermobility

Araujo and Chaves2 evaluated, using the Flexitest, 125 women with a mean age of 50 years, with 31 of them presenting MVP. They verified that the women with a mitral valve prolapse are approximately 15% more flexible. The Flexitest score was significantly higher in women with MVP in 13 of the 20 joints assessed.

In a similar study, the authors analyzed retrospectively 124 consecutive assessments of adult, non-athlete women carried out in a specialized clinic, of which 34 had a diagnosis of MVP and 90 did not have a diagnosis or clinical evidence of the disease. Body mass index, conventional electrocardiogram, manual prehension with a dynamometer, sit-and-stand test and Flexitest to assess flexibility were verified.

The sit-and-stand test is simple, reliable and fast test to evaluate the dexterity of the actions of sitting and standing from the ground. The interpretation is made for each action, with scores from 0 to 5.

The cineanthropometric variables, notably body weight, flexibility, presence of signs of joint hypermobility and dexterity to sit and stand up from the ground were the ones that better differentiated individuals with from those without MVP, a condition that suggests the inclusion of the analysis of cineanthropometric variables in the assessment of adult women with suspected or diagnosed MVP6.

Yazici et al.25 investigated the prevalence of the Benign Joint Hypermobility Syndrome (BJHS) in individuals with mitral valve prolapse (MVP) and the correlation between the echocardiographic characteristics of the mitral valve, the elastic properties of the aortic wall and the index of hypermobility of Beighton-Horan. They analyzed 46 patients with prolapse, with a mean age of 26.1 yrs, of which 39 were women and 25 healthy individuals (3 mean and 22 women with a mean age of 25.4 yrs). The presence of BJHS was assessed according to the criteria of Beighton-Horan. The prevalence of BJHS in patients with MVP was significantly higher in the healthy individuals, 45.6% vs. 12% (p< 0.001). The group with MVP+BJHS presented significantly increased thickness of the anterior mitral leaflet (p<0.001). Yazici e cols.25 concluded that the prevalence of BJHS in individuals with MVP was more frequent than in the general population, considering that the prevalence of BJHS in patients with MVP was 45%.

Martin-Santos et al.16 sought to evaluate whether the Hypermobility Syndrome was more frequent in patients with panic syndrome, agoraphobia or both and determine if the mitral valve prolapse modified or collaborated in part with the association. A total of 99 patients, who had been recently diagnosed and were not undergoing any treatment for panic syndrome and agoraphobia and 64 patients who had never presented any anxiety disorder participated in the study. The method consisted in a clinical interview, criteria of Beighton-Horan and echocardiogram. The hypermobility syndrome was found in 67.7% of the patients with anxiety disorder, with the latter presenting a 16-fold increased chance of having hypermobility. The MVP was present in 5.4% of the patients with panic disorders and in 17.7% of the control patients.

JH is significantly prevalent in patients with panic disorder, agoraphobia or both and can reflect a predisposition to suffer from anxiety, whereas the MVP has a secondary role in the association between hypermobility and anxiety16, the result of occasional alterations in the scarce collagen of the central nervous tissue14.

Gulpek et al.26, with the same objective, analyzed 115 individuals divided in 3 groups: Group 1 (n=42), patients with panic disorder with MVP; Group 2 (n=35), patients with panic disorder without MVP; and Group 3 (n=38), control group: individuals with MVP without any psychiatric disorder. The authors used the criteria by Beighton-Horan to assess the hypermobility syndrome and a two-dimensional echocardiogram to detect the MVP. The hypermobility syndrome was identified in 59.5% of the patients with panic disorder and MVP, in 42.9% of the patients without MVP and in 52.6% of the control group. Gulpek et al 26 no significant association was observed between the panic disorder and the hypermobility syndrome.

Cardiovascular disease with a higher risk of death is common in Marfan syndrome and these individuals present JH. It is a hereditary disease of the conjunctive tissue, of genetic origin, autosomal dominant, with variable expression; it affects mainly the skeletal, ocular and cardiovascular systems. The estimated prevalence is 1/10,000 individuals. The origin of the disease is in the mutation of the fibrillin gene (FBN-1), which is located in chromosome 15. The main cardiovascular alterations are the annuloaortic ectasia and the mitral valve prolapse9,15. Lopez et al.14 evaluated 21 children with Marfan syndrome, of which 62% of them were males, aged 9 months to 16 years. At the echocardiographic assessment, 52% of the patients presented valvular prolapse.

 

Final considerations

Joint hypermobility has been the object of several discussions as it affects the common population, predisposing these individuals to several organic alterations, of which the etiology is still debatable. Its characteristic is related to a genetic disorder of the conjunctive tissue that can cause pain and musculoskeletal alterations. The MVP is also a genetic disorder of the conjunctive tissue with possible chromosomal alterations, which affects the mitral valve and is diagnosed in 2.4% of the general population.

The inclusion of tests that measure the joint mobility in the clinical assessment can be relevant, as the identification of JH must lead to the investigation of several alterations that result from this genetic characteristic, including the MVP, thus providing early diagnosis and treatment, considering that the condition many times has an asymptomatic evolution. However, there is a lack of studies that can confirm the association between JH and the evolution and severity of MVP.

The genetic alterations in collagen composition seem to be the main cause of JH and MVP. However, there are no studies that can confirm this association, although they present high prevalence among them. Studies have also associated the MVP, JH and anxiety and panic disorders, which probably present associations caused by collagen alterations, resulting from occasional alterations in the scarce collagen of the central nervous tissue.

Few studies have correlated the mitral valve prolapse and JH using several methods of assessment. Furthermore, the methods used to evaluate joint mobility in several health conditions are considered outdated and limited. There is also need for histopathological studies associated to physical tests to confirm the effectiveness of these tests, associating them to the structural alterations of the joint components.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

Study Association

This article is part of the thesis of master submitted by Simone Cavenaghi, from Faculdade de Medicina de São José do Rio Preto.

 

References

1. Egri D, Yoshinari NH. Hipermobilidade articular generalizada. Rev Bras Reumatol. 1999; 39 (4): 231-6.         [ Links ]

2. Araújo CGS, Chaves CPG. Adult women with mitral valve prolapse are more flexibe. Br J Sports Med. 2005; 39: 720-4.         [ Links ]

3. Levine RA, Slaugenhaupt SA. Molecular genetics of mitral valve prolapse. Curr Opin Cardiol. 2007; 22 (3): 171-5.         [ Links ]

4. Freed LA, Acierno JS Jr, Dai D, Leyne M, Marshall JE, Nesta F, et al. A locus for autosomal dominant mitral valve prolapse on chromosome 11p15.4. Am J Hum Genet. 2003; 72: 1551-9.         [ Links ]

5. Leal JC, Gregori F Jr, Galina LE, Thevenard RS, Braile DM. Avaliação ecocardiográfica em pacientes submetidos à substituição de cordas tendíneas rotas. Braz J Cardiovasc Surg. 2007; 22 (2): 184-91.         [ Links ]

6. Araújo CGS, Chaves CPG. Prolapso da valva mitral em mulheres adultas: características clínicas, fisiológicas e cineantropométricas. Rev SOCERJ. 2007; 20 (2): 112-20.         [ Links ]

7. Scordo KA. Mitral valve prolapse syndrome health concerns, symptoms and treatments. West J Nurs Res. 2005; 27 (4): 390-405.         [ Links ]

8. Savage D, Garrison R, Devereux R, Castelli W, Anderson S, Levy D. Mitral valve prolapse in the general population. I. Epidemiologic features: The Framingham Study. Am Heart J. 1983; 106: 571-6.         [ Links ]

9. Weyman AE, Scherrer-Crosbie M. Marfan syndrome and mitral valve prolapse. The J Clin Invest. 2004; 114: 1543-6.         [ Links ]

10. Ismajli J, Shabani X, Manaj R, Emini M, Bajraktari G. Mitral valve prolapse, atrial flutter, and syncope in a young female patient. Med Sci Monit. 2006; 12 (11): 110-3.         [ Links ]

11. Hayek E, Gring CN, Griffin BP. Mitral valve prolapse. Lancet. 2005; 365: 507-18.         [ Links ]

12. França HH. Uma interpretação da síndrome do prolapso da válvula mitral. Arq Bras Cardiol. 2000; 74 (5): 453-5.         [ Links ]

13. Nesta F, Leyne M, Yosefy C, Simpson C, Dai D, Marshall JE, et al. New locus for autosomal dominant mitral valve prolapse on chromosome 13. Circulation. 2005; 112: 2022-30.         [ Links ]

14. Lopez VMO, Perez ABA, Moisés VA, Gomes L, Pedreira PS, Silva CC, et al. Avaliação clínico-cardiológica e ecocardiográfica, sequencial, em crianças portadoras da Síndrome de Marfan. Arq Bras Cardiol. 2005; 85 (5): 314-8.         [ Links ]

15. Correia J, Rodrigues D, Silva AM, Sá e Melo A, Providência LA. Calcificação maciça do anel mitral numa adolescente com Síndrome de Marfan: um caso clínico. Rev Port Cardiol. 2006; 25 (10): 921-6.         [ Links ]

16. Martin-Santos R, Bulbena A, Porta M, Gago J, Molina L, Duro JC. Association between joint hipermobility syndrome and panic disorder. Am J Psychiatr. 1998; 155 (11): 1578-83.         [ Links ]

17. Perretto S, Silva MB, Skare T, Magro CE, Guidolin F. Correlação entre prolapso de valva mitral e disfunção tireoidiana na população lúpica. Rev Soc Bras Clin Med. 2004; 2 (6): 165-7.         [ Links ]

18. Lamari NM, Chueire AG, Cordeiro JA. Analysis of joint mobility patterns among preschool children. Sao Paulo Med J. 2005; 123(3): 119-23.         [ Links ]

19. Malfait F, Hakim AJ, De Paepe A, Grahame R. The genetic basis of the joint hypermobility syndromes. Rheumatology. 2006; 45: 502-7.         [ Links ]

20. Cavenaghi S, Folchine AER, Marino LHC, Lamari NM. Prevalência de hipermobilidade articular e sintomas álgicos em trabalhadores industriais. Arq ciênc saúde. 2006; 13 (2): 66-70.         [ Links ]

21. Lamari NM, Marino LC, Cordeiro JA, Pellegrini AM. Flexibilidade anterior do tronco adolecente após o pico da velocidade de crescimento em estatura. Acta Ortop Bras. 2007; 15 (1): 25-29.         [ Links ]

22. Hakim AJ, Cherkas LF, Grahame R, Spector TD, Macgregor A. The genetic epidemiology of joint hypermobility. Arthritis Rheumatism. 2004; 50 (8): 2640-4.         [ Links ]

23. Grahame R. Joint hypermobility and genetic collagen disorders: are they related?. Arch Dis Child. 1999; 80: 188-91.         [ Links ]

24. Araújo CGS. Correlação entre diferentes métodos lineares e adimensionais de avaliação da mobilidade articular. Rev Bras Ciên e Mov. 2000; 8 (2): 25-32.         [ Links ]

25. Yazici M, Ataoglu S, Makarç S, Kolbas M, Erbilen E, Albayrak S, et al. The relationship between echocardiographic features of mitral valve and elastic properties of aortic wall and beighton hypermobility score in patients with mitral valve prolapse. Romatizma. 2002; 17 (2): 67-76.         [ Links ]

26. Gulpek D, Bayraktar E, Akbay SP, Capaci K, Kayikcioglu M, Alivev E, et al. Joint hypermobility syndrome and mitral valve prolapse in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Sep; 28(6): 969-73.         [ Links ]

 

 

Mailing address:
Simone Cavenaghi
Rua Paraná, 66, Boa Vista
15.025-140, São José do Rio Preto, SP, Brasil
E-mail: sicavenaghi@ig.com.br

Manuscript received March 23, 2008; revised manuscript received July 04, 2008; accepted September 22, 2008.

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License